美国 · 股市与财经 · Yahoo Finance

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

来源：Yahoo Finance · 美国 10 小时前

BEIJING, Oct. 11, 2026 (GLOBE NEWSWIRE) -- (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced…

在 Yahoo Finance 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (finance.yahoo.com)

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

推荐阅读

XRP Ledger defends emergency patch for unlimited XRP bug

Trump's Russia-Ukraine Energy Ceasefire May Only Cover Oil Refineries

Judge orders Trump admin to stop airing challenged government-funded ads immediately

Amazon in talks to acquire AI startup Decart for $7B: WSJ

The movie about a Facebook whistleblower who leaked incriminating details disappoints, and ‘The Social Reckoning’ will likely lag ‘The Social Network’

Will the HomeView be Apple’s first smart home success?

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

分享

推荐阅读

XRP Ledger defends emergency patch for unlimited XRP bug

Trump's Russia-Ukraine Energy Ceasefire May Only Cover Oil Refineries

Judge orders Trump admin to stop airing challenged government-funded ads immediately

Amazon in talks to acquire AI startup Decart for $7B: WSJ

The movie about a Facebook whistleblower who leaked incriminating details disappoints, and ‘The Social Reckoning’ will likely lag ‘The Social Network’

Will the HomeView be Apple’s first smart home success?